Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

epirubicin

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Generic mfg.

Drug class:

Topoisomerase II inhibitor

Related drugs:

‹

doxorubicin hydrochloride (87)

etoposide IV (53)

etoposide oral (33)

pegylated liposomal doxorubicin (31)

daunorubicin (20)

cytarabine/daunorubicin liposomal formulation (19)

idarubicin hydrochloride (16)

mitoxantrone (16)

dactinomycin (8)

non-pegylated liposomal doxorubicin (3)

pegylated liposomal doxorubicin (1)

zoptarelin doxorubicin (1)

mitoxantrone liposomal (0)

H-ferritin–nanocaged doxorubicin (0)

non-pegylated liposomal doxorubicin (0)

lyso-thermosensitive liposomal doxorubicin (0)

tirapazamine (0)

dexrazoxane (0)

doxorubicin liposomal (0)

›

No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2	ifosfamide + epirubicin + mesna Sensitive: A2 - Guideline ifosfamide + epirubicin + mesna Sensitive : A2
No biomarker	Sarcoma	No biomarker	Sarcoma	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
No biomarker	Nasopharyngeal Carcinoma	No biomarker	Nasopharyngeal Carcinoma	cisplatin + paclitaxel + epirubicin Sensitive: A2 - Guideline cisplatin + paclitaxel + epirubicin Sensitive : A2	cisplatin + paclitaxel + epirubicin Sensitive: A2 - Guideline cisplatin + paclitaxel + epirubicin Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
HER-2 negative	HER2 Negative Breast Cancer	HER-2 negative	HER2 Negative Breast Cancer	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2	epirubicin Sensitive: A2 - Guideline epirubicin Sensitive : A2
MSH3 overexpression	Soft Tissue Sarcoma	MSH3 overexpression	Soft Tissue Sarcoma	ifosfamide + epirubicin Resistant: B - Late Trials ifosfamide + epirubicin Resistant : B	ifosfamide + epirubicin Resistant: B - Late Trials ifosfamide + epirubicin Resistant : B
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	paclitaxel + cyclophosphamide + epirubicin Sensitive: B - Late Trials paclitaxel + cyclophosphamide + epirubicin Sensitive : B	paclitaxel + cyclophosphamide + epirubicin Sensitive: B - Late Trials paclitaxel + cyclophosphamide + epirubicin Sensitive : B
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	epirubicin Sensitive: C2 – Inclusion Criteria epirubicin Sensitive : C2	epirubicin Sensitive: C2 – Inclusion Criteria epirubicin Sensitive : C2
HR positive	HER2 Negative Breast Cancer	HR positive	HER2 Negative Breast Cancer	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3
UNC13D mutation	HER2 Negative Breast Cancer	UNC13D mutation	HER2 Negative Breast Cancer	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3	epirubicin + vinorelbine tartrate Sensitive: C3 – Early Trials epirubicin + vinorelbine tartrate Sensitive : C3
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	docetaxel + epirubicin Sensitive: C3 – Early Trials docetaxel + epirubicin Sensitive : C3	docetaxel + epirubicin Sensitive: C3 – Early Trials docetaxel + epirubicin Sensitive : C3
KMT2D mutation	Triple Negative Breast Cancer	KMT2D mutation	Triple Negative Breast Cancer	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3	cyclophosphamide + epirubicin Resistant: C3 – Early Trials cyclophosphamide + epirubicin Resistant : C3